Y13g dihydrochloride is a dual-target small molecule inhibitor of IL-6 and acetylcholinesterase, pathways implicated in Alzheimer's disease. It has demonstrated efficacy in reversing memory deficits in an STZ-induced rodent model of cognitive impairment, with associated improvements in histopathological markers. This compound is a valuable research tool for investigating neuroinflammation and cholinergic dysfunction in AD.